Gregory E. Fosheim
![](https://www.healthlifesciencesnews.com/wp-content/uploads/2020/04/rss.png)
Gregory (Greg) E. Fosheim provides counsel on a wide array of corporate, transactional and regulatory compliance matters across the healthcare and life sciences industry. Drawing on his extensive laboratory and public health background, he regularly advises on clinical and diagnostic laboratory matters, anatomic pathology and fertility laboratory compliance. Greg represents hospitals, health systems and physician practice management companies in all aspects of transactional and operational matters, particularly those with regulatory, licensing, accreditation and policy considerations. He has also negotiated several acquisitions and sales of proton therapy centers. Read Gregory's full bio.
CMS Issues FAQs to Aid Pharmacies in Preparing for Medicare Part B Coverage of PrEP Medications
By Gregory E. Fosheim, Monica Wallace, Emily Jane Cook and Jae Hyun Lee on Jun 26, 2024
Posted In Hospitals & Health Systems, Life Sciences, Managed Care
As we previously advised, the Centers for Medicare & Medicaid Services (CMS) is preparing to issue a national coverage determination (NCD) for pre-exposure prophylaxis (PrEP) using antiretroviral drugs to prevent HIV under Medicare Part B. In response to questions from stakeholders, CMS released FAQs on June 25, 2024, to guide pharmacies through certain enrollment and...
Continue Reading
CMS Advises Preparatory Steps for Anticipated PrEP Coverage Transition to Medicare Part B
By Monica Wallace, Emily Jane Cook, Gregory E. Fosheim and Jae Hyun Lee on Apr 25, 2024
Posted In Life Sciences
On April 15, the Centers for Medicare & Medicaid Services (CMS) released a fact sheet on the potential national coverage determination (NCD) for pre-exposure prophylaxis (PrEP) using antiretroviral drugs to prevent HIV. CMS did not announce any coverage changes in the fact sheet but is providing advance information to avoid any possible disruptions to beneficiaries...
Continue Reading